EKIMAS Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ASNB research report →
Company
EKIMAS Corporation does not have significant operations. Previously, the company was engaged in the development of polymer materials for use in the design and development of medical devices used for treating a range of anatomical sites and disease states. It intends to identify, acquire, or merge with an operating company through an equity-based exchange transaction.
- CEO
- Henrik Rouf
- IPO
- 1996
- Employees
- 11
- HQ
- Las Vegas, NV, US
Price Chart
Valuation
- Market Cap
- $4.83M
- P/E
- -16.45
- P/S
- 0.00
- P/B
- 1.16
- EV/EBITDA
- -18.16
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -7.18%
- ROIC
- -5.38%
Growth & Income
- Revenue
- $5.00K · 0.00%
- Net Income
- $-2,901,321 · 0.00%
- EPS
- $-0.32 · 0.00%
- Op Income
- $-2,919,365
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $1.70
- 52W Low
- $0.55
- 50D MA
- $0.80
- 200D MA
- $0.92
- Beta
- -0.58
- Avg Volume
- 2.06K
Get TickerSpark's AI analysis on ASNB
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ASNB Coverage
We haven't published any research on ASNB yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ASNB Report →